Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

被引：122
|
作者：
Focosi, Daniele [1 ]
Maggi, Fabrizio [2 ]
机构：
[1] Pisa Univ Hosp, North Western Tuscany Blood Bank, I-56124 Pisa, Italy
[2] Univ Insubria, Dept Med & Surg, Varese, Italy
来源：
REVIEWS IN MEDICAL VIROLOGY | 2021年 / 31卷 / 06期
关键词：
B.1.1.7; B.1.351; BNT162b2; bamlanivimab; casirivimab; convalescent plasma; COVID-19; etesevimab; imdevimab; immune escape; LyCoV016; LY-CoV555; mRNA-1273; mutations; neutralising antibody; REGN10987; REGN10933; P.1; P.2; polyclonal immunoglobulins; SARS-CoV-2; RECEPTOR-BINDING DOMAIN; MUTATIONS; REINFECTION; INFECTION;
D O I：
10.1002/rmv.2231
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains.
引用
收藏
页数：21
相关论文
共 50 条
  • [21] Durability of SARS-CoV-2 Spike Antibody Levels in Dialysis Patients After COVID-19 Infection
    Manley, Harold J.
    Hsu, Caroline M.
    Aweh, Gideon N.
    Weiner, Daniel E.
    Frament, Jill M.
    Ladik, Vladimir
    Johnson, Doug
    Lacson, Eduardo K.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 100 - 101
  • [22] A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
    Tiong Kit Tan
    Pramila Rijal
    Rolle Rahikainen
    Anthony H. Keeble
    Lisa Schimanski
    Saira Hussain
    Ruth Harvey
    Jack W. P. Hayes
    Jane C. Edwards
    Rebecca K. McLean
    Veronica Martini
    Miriam Pedrera
    Nazia Thakur
    Carina Conceicao
    Isabelle Dietrich
    Holly Shelton
    Anna Ludi
    Ginette Wilsden
    Clare Browning
    Adrian K. Zagrajek
    Dagmara Bialy
    Sushant Bhat
    Phoebe Stevenson-Leggett
    Philippa Hollinghurst
    Matthew Tully
    Katy Moffat
    Chris Chiu
    Ryan Waters
    Ashley Gray
    Mehreen Azhar
    Valerie Mioulet
    Joseph Newman
    Amin S. Asfor
    Alison Burman
    Sylvia Crossley
    John A. Hammond
    Elma Tchilian
    Bryan Charleston
    Dalan Bailey
    Tobias J. Tuthill
    Simon P. Graham
    Helen M. E. Duyvesteyn
    Tomas Malinauskas
    Jiandong Huo
    Julia A. Tree
    Karen R. Buttigieg
    Raymond J. Owens
    Miles W. Carroll
    Rodney S. Daniels
    John W. McCauley
    Nature Communications, 12
  • [23] SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
    Velusamy, Palaniyandi
    Kiruba, Kannan
    Su, Chia-Hung
    Arun, Viswanathan
    Anbu, Periasamy
    Gopinath, Subash C. B.
    Vaseeharan, Baskaralingam
    JOURNAL OF KING SAUD UNIVERSITY SCIENCE, 2021, 33 (08)
  • [24] Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
    McCarthy, Kevin R.
    Rennick, Linda J.
    Nambulli, Sham
    Robinson-McCarthy, Lindsey R.
    Bain, William G.
    Haidar, Ghady
    Duprex, W. Paul
    SCIENCE, 2021, 371 (6534) : 1139 - +
  • [25] Monoclonal antibody therapy in COVID-19 induced by SARS-CoV-2
    Conti, P.
    Pregliasco, F. E.
    Calvisi, V.
    Caraffa, A.
    Gallenga, C. E.
    Kritas, S. K.
    Ronconi, G.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (02): : 423 - 427
  • [26] Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients
    Deshpande, Gururaj Rao
    Sapkal, Gajanan N.
    Tilekar, Bipin N.
    Yadav, Pragya D.
    Gurav, Yogesh
    Gaikwad, Shivshankar
    Kaushal, Himanshu
    Deshpande, Ketki S.
    Kaduskar, Ojas
    Sarkale, Prasad
    Baradkar, Srikant
    Suryawanshi, Annasaheb
    Lakra, Rajen
    Sugunan, A. P.
    Balakrishnan, Anukumar
    Abraham, Priya
    Salve, Pavan
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (01) : 82 - 87
  • [27] SARS-CoV-2 Spike Proteins: A Key Target for COVID-19 Therapeutics Development
    Kohli, Khushi
    Liu, Samuel
    Garapaty, Arjun
    FASEB JOURNAL, 2021, 35
  • [28] Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections
    Lei, Qing
    Li, Yang
    Hou, Hong-yan
    Wang, Feng
    Ouyang, Zhu-qing
    Zhang, Yandi
    Lai, Dan-yun
    Banga Ndzouboukou, Jo-Lewis
    Xu, Zhao-wei
    Zhang, Bo
    Chen, Hong
    Xue, Jun-biao
    Lin, Xiao-song
    Zheng, Yun-xiao
    Yao, Zong-jie
    Wang, Xue-ning
    Yu, Cai-zheng
    Jiang, He-wei
    Zhang, Hai-nan
    Qi, Huan
    Guo, Shu-juan
    Huang, Sheng-hai
    Sun, Zi-yong
    Tao, Sheng-ce
    Fan, Xiong-lin
    ALLERGY, 2021, 76 (02) : 551 - 561
  • [29] The role of SARS-CoV-2 antibody therapy in the treatment of COVID-19
    Fabian Akos
    ORVOSI HETILAP, 2021, 162 (51) : 2030 - 2039
  • [30] Using SARS-CoV-2 Antibody Testing in COVID-19 Research
    Amraotkar, Alok R.
    Keith, Rachel J.
    Palmer, Kenneth E.
    Bhatnagar, Aruni
    AMERICAN JOURNAL OF MEDICINE, 2023, 136 (06): : 501 - 503
12345